Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

References

• The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Braunwald E, Fauci A, Kasper D, et al. Harrison’s Principles of Internal Medicine, 15th edn. New York: McGraw-Hill, 2001
   Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26: 3080–6
   Google Scholar
• The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86
   PubMed Web of Science ®Google Scholar
• Barnett AH. Treating to goal: challenges of current management. Eur J Endocrinol 2004;151(Suppl 2):T3–T7
   PubMedGoogle Scholar
• Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999;15:42–6
   PubMed Web of Science ®Google Scholar
• Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004;65(Suppl 1):S23–7
   PubMedGoogle Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–91
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–100
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628–35
   PubMed Web of Science ®Google Scholar
• Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006;82:280–4
   PubMed Web of Science ®Google Scholar
• Henry RR, Ratner RE, Stonehouse AH, et al. Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes (abstract 485-P). Diabetes 2006; 55(Suppl 1):A116
   Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559–69
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5–26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27–40
   PubMed Web of Science ®Google Scholar
• Wilson PW, Anderson KM, Harris T, et al. Determinants of change in total cholesterol and HDL-C with age: the Framingham study. J Gerontol 1994;49:M252–7
   PubMedGoogle Scholar
• UKPDS Group. Plasma lipids and lipoproteins at diagnosis of NIDDM: effects of age and gender (UKPDS 27). Diabetes Care 1997;20:1683–7
   PubMed Web of Science ®Google Scholar
• Netten A, Curtis L. Unit costs of health and social care 2003. http://www.pssru.ac.uk/pdf/uc2003/uc2003_inflation.pdf. 2004. [Last accessed 25 April 2006]
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22: 340–9
   Google Scholar
• Australian Institute of Health and Welfare. The Burden of Disease and Injury in Australia, 2003
   Google Scholar
• Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583–637
   PubMed Web of Science ®Google Scholar
• Matza L, Secnik K, Yurgin NR, et al. Standard gamble assessment of utilities for type 2 diabetes treatment-related attributes. ISPOR, 11th International Meeting, 2006
   Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217–30
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003;2:33–47
   PubMedGoogle Scholar
• Tarn T, Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004;10:5–15
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003;6:9–17
   PubMed Web of Science ®Google Scholar
• Yurgin NR, Secnik K, Cottrell S. Blood glucose monitoring recommendations and practices in patients with type 2 diabetes: a survey of healthcare professionals and patients in the UK. Value Health 2006;9:A42
   Google Scholar
• Barnett AH. Exenatide. Drugs Today (Barc ) 2005;41:563–78
   PubMed Web of Science ®Google Scholar
• Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327–40
   Google Scholar
• Dennett SL, Secnik K, Yurgin NR, McDonald-Everett CM. The impact of body weight on utility scores in patients with type 2 diabetes. Value Health 2006;9:A326
   Google Scholar
• Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238–43
   PubMed Web of Science ®Google Scholar
• Hakim Z, Wolf A, Garrison LP. Estimating the effect of changes in body mass index on health state preferences. Pharmaco-economics 2002;20:393–404
   Google Scholar
• Lee AJ, Morgan CL, Morrissey M, et al. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with type 1 diabetes, type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005;22:1482–6
   PubMed Web of Science ®Google Scholar
• Secnik K, Matza L, Yurgin NR, et al. Patient-reported utilities/ disutilities associated with treatments for type 2 diabetes. Value Health 2006;9:A42
   Web of Science ®Google Scholar
• Morgan CL, Peters JR, McEwan P, et al. The association between obesity (BMI) and health-related utility in subjects with type 1 and type 2 diabetes. 40th Annual meeting of the European Association for the Study of Diabetes (EASD), September 5–9, 2004
   Google Scholar
• Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458–63
   PubMed Web of Science ®Google Scholar
• Currie CJ, Peters JP, Morissey M, et al. Evaluation of the association between health-related utility and obesity in hospital treated subjects. ISPOR 9th Annual International Meeting, May 16, 2004
   Google Scholar
• Dixon S, Currie CJ, McEwan P. Utility values for obesity and preliminary analysis of the health outcomes data repository. Expert Rev Pharmacoeconom Outcome Res 2004;4:657–65
   PubMedGoogle Scholar
• Groessi EJ, Kaplan RM, Barrett-Connor E, et al. Body mass index and quality of well-being in a community of older adults. Am J Prev Med 2006;26:126–9
   Google Scholar
• Jia H, Lubetkin EI. The impact of obesity on health-related quality of life in the general adult US population. J Public Health (Oxf) 2005;27:156–64
   PubMed Web of Science ®Google Scholar
• Kortt MA, Clarke PM. Estimating utility values for health states of overweight and obese individuals using the SF-36. Qual Life Res 2005;14:2177–85
   PubMed Web of Science ®Google Scholar
• Livingston EH, Ko CY. Use of the health and activities limitation index as a measure of quality of life in obesity. Obes Res 2002;10:824–32
   PubMedGoogle Scholar
• Kannel WB, D’Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med 1999;159:1197–204
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D, et al. Effects of exenatide compared with twice-daily biphasic insulin aspart in patients with type 2 diabetes using sulphonylurea and metformin. Diabetologia 2006;49\(Suppl 1):3 (Abstract 001)
   Google Scholar
• Barnett AH, Trautmann M, Burger J, et al. A comparison of exenatide and insulin glargine in patients using a single oral anti-diabetic agent. Diabetologia 2006;49\(Suppl 1):474 (Abstract 782)
   Google Scholar
• Zinman B, Hoogwerf B, Garcia SD, et al. Safety and efficacy of exenatide over 16 weeks in patients with type 2 diabetes mellitus using a thiazolidenedione with or without metformin. Diabetologia 2006;49\(Suppl 1):475 (Abstract 782)
   Google Scholar
• Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436–47
   PubMed Web of Science ®Google Scholar
• Benedetti MM, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189–96
   PubMed Web of Science ®Google Scholar
• Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138: 952–9
   Google Scholar
• Rosenstock J, Schwartz SL, Clark CM, Jr., et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631–6
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23: 1130–6
   Google Scholar
• Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28: 950–5
   Google Scholar
• U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: US Renal Data System; 2006
   Google Scholar
• Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442–50
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 1998;21:42–8
   Google Scholar
• United Kingdom Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;317:720–6
   PubMed Web of Science ®Google Scholar
• NHS UK Transplant Statistics. 2002
   Google Scholar
• Ghatnekar O. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four different European countries. J Wound Care 2002;11:70
   PubMedGoogle Scholar
• Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176–80
   PubMed Web of Science ®Google Scholar
• Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003;20:586–93
   PubMed Web of Science ®Google Scholar
• James M, Turner DA, Broadbent DM, et al. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 2000;320:1627–31
   PubMed Web of Science ®Google Scholar
• OMNILABS (UK) Limited, Price List, effective October 2000, London. 2000
   Google Scholar